Sitomet® is a combination of two anti-hyperglycemic agents-Sitagliptin Phosphate Monohydrate
and Metformin Hydrochloride with complementary mechanisms of action to improve glycemic
control in patients with type 2 diabetes.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the
inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1(GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the
day and levels are increased in response to a meal. These hormones are rapidly inactivated by the
enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic
regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated,
GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular
signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic
alpha cells, leading to reduced hepatic glucose production.
Metformin Hydrochloride is a member of biguanide class. The pharmacologic mechanism of action
of Metformin is different from other classes of oral anti-hyperglycemic agents. Metformin decreases
hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral
glucose uptake and utilization.
Your shopping cart is empty!